IP Library › Granted Patent US 12,251,376
Granted Patent B2
US 12,251,376 · App. 17/429,902 · Granted Mar 18, 2025

Combinations with thiazolidinediones for use in the prevention or treatment of abnormal bone growth

Inventors: Rodolfo Gómez Bahamonde (Santiago de Compostela, ES); Eloi Franco Trepat (Santiago de Compostela, ES); Ana Alonso Pérez (Santiago de Compostela, ES); María Guillán Fresco (Santiago de Compostela, ES); Alberto Jorge Mora (Santiago de Compostela, ES)
Assignees: SERVIZO GALEGO DE SAÚDE (SERGAS); FUNDACIÓN PÚBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA
A61K31/4439A61K31/405A61K31/573A61P19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,251,376
App. No.
17/429,902
Granted
Mar 18, 2025
Kind
B2
Abstract

The present invention refers to the use of thiazolidinediones (preferably rosiglitazone and/or pioglitazone) in the prevention or treatment abnormal bone growth selected from the list comprising: heterotopic ossification, osteophytes and/or syndesmophytes. According to the present invention, thiazolidinediones can be combined with corticoids and/or anti-inflammatory drugs (preferably non-steroidal anti-inflammatory drugs).

Claims (13)

1. A method for preventing or treating abnormal bone growth in a subject, the method comprising administering to the subject a therapeutically effective amount of a combination drug product comprising:

a thiazolidinedione selected from the group consisting of rosiglitazone, pioglitazone, or a combination thereof;

a corticoid comprising dexamethasone; and

an anti-inflammatory drug comprising indomethacin.

2. The method according to claim 1 , wherein the thiazolidinedione is rosiglitazone or pioglitazone.

3. The method according to claim 1 , wherein the corticoid is dexamethasone.

4. The method according to claim 1 , wherein the anti-inflammatory drug is indomethacin.

5. The method according to claim 1 , wherein the thiazolidinedione, the corticoid and the anti-inflammatory drug are administered together.

6. The method according to claim 1 , wherein the thiazolidinedione, the corticoid and the anti-inflammatory drug are not administered together.

7. The method according to claim 1 , wherein the thiazolidinedione, the corticoid and the anti-inflammatory drug are administered by a route independently selected from the group consisting of an oral administration, an intravenous administration and a local administration.

8. The method according to claim 1 , wherein the abnormal bone growth is selected from the group consisting of a heterotopic ossification, an osteophyte, a syndesmophyte, and any combination thereof.

9. The method according to claim 1 , wherein the abnormal bone growth is acute or chronic heterotopic ossification.

10. The method according to claim 1 , wherein the abnormal bone growth includes a heterotopic ossification in at least one soft tissue.

Assignments (3)
CHANGE OF NAME Recorded Nov 14, 2024
From: FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA
To: FUNDACIÓN PÚBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA
Reel/Frame 069265/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: ALONSO PÉREZ, ANA; GUILLÁN FRESCO, MARÍA
To: FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA
Reel/Frame 060090/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: GÓMEZ BAHAMONDE, RODOLFO; FRANCO TREPAT, ELOI; JORGE MORA, ALBERTO
To: SERVIZO GALEGO DE SAÚDE (SERGAS)
Reel/Frame 060090/0190 →
Priority Claims (1)
EP 19382094 · Feb 11, 2019 · regional
Continuity (1)
Related Publication 20220288044A1 · Sep 15, 2022
References Cited (19)
CN 106754664A · 2017 [cited by applicant]
CN 108057031A · 2018 [cited by applicant]
CN 108192860A · 2018 [cited by applicant]
WO 2010037130A2 · 2010 [cited by applicant]
WO 2010037130A3 · 2010 [cited by applicant]
WO 2013006372A1 · 2013 [cited by applicant]
Contador D, Ezquer F, Espinosa M, Arango-Rodriguez M, Puebla C, Sobrevia L, Conget P. Dexamethasone and rosiglitazone are sufficient and necessary for producing functional adipocytes from mesenchymal stem cells. Exp Bio… [cited by examiner]
Jiao Li, Bin Zuo, Li Zhang, Liming Dai, Xiaoling Zhang; Osteoblast versus Adipocyte: Bone Marrow Microenvironment-Guided Epigenetic Control. Case Rep Orthop Res Jan. 11, 2019; 1 (1-3): 2-18. Published online Jun. 7, 201… [cited by examiner]
Sinha S, Uchibe K, Usami Y, Pacifici M, Iwamoto M. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent. Bone. Sep. 2016;90:59-68.… [cited by examiner]
Takahashi et al., “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” [cited by applicant]
Waddington, “The Strategy of the Genes: A Discussion of Some Aspects of Theoretical Biology,” [cited by applicant]
Anghel et al., “Fat poetry: a kingdom for PPARγ,” [cited by applicant]
Gatti et al., “Rosiglitazone Therapy is Associated with Major Clinical Improvements in a Patient With Fibrodysplasia Ossificans Progressiva,” [cited by applicant]
Hegele, “Lessons from human mutations in PPARγ,” [cited by applicant]
Janderová et al., “Human Mesenchymal Stem Cells as an in Vitro Model for Human Adipogenesis,” [cited by applicant]
Lowell, “PPARγ: An Essential Regulator of Adipogenesis and Modulator of Fat Cell Function,” [cited by applicant]
Sandhu et al., “LDL-cholesterol concentrations: a genome-wide association study,” [cited by applicant]
Shockley et al., “PPARγ2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells,” [cited by applicant]
Yun et al., “Inhibition of PPARγ2 Gene Expression by the HIF-1-Regulated Gene DECI/Stra13: A Mechanism for Regulation of Adipogenesis by Hypoxia,” [cited by applicant]